Notifications
Back
SHIFTBIO Pipeline,
In Vivo Cell Therapy 


Our pipelines demonstrate broad expandability across various therapeutic areas thanks to the versatility and cargo flexibility of Natural Drug Delivery Platforms technologies

 

SIRP-NNP-MSC
Program
Indication(s)Inflammatory and Autoimmune Diseases
Targeting moietySIRPα
Therapeutic cargoMesencymal stem cell factors
SIRP-NNP-ASO
Program
Indication(s)Inflammatory Bowel Disease
Targeting moietySIRPα
Therapeutic cargoNLRP3 ASO
SIRP-NNP-siRNA
Program
Indication(s)Cold Tumor
Targeting moietySIRPα
Therapeutic cargoUndisclosed
CBD-NNP-HIF1α
Program
Indication(s)Diabetic Ulcer
Targeting moietyCollagen binding domain
Therapeutic cargoHIF1α transcription factor
Ape-C-NNP
Program
Indication(s)Pulmonary Arterial Hypertension
Targeting moietyCAR peptide
Therapeutic cargoApelin peptide
dtBBB-NNP-Oligo
Program
Indication(s)Alzheimer's Disease
Targeting moietyUndisclosed
Therapeutic cargoUndisclosed

SHIFTBIO Pipeline
In Vivo Cell Therapy


Our pipelines demonstrate broad expandability across various therapeutic areas

thanks to the versatility and cargo flexibility of Natural Drug Delivery Platform technologies


SIRP-NNP-MSC
SIRP-NNP-ASO
SIRP-NNP-siRNA
CBD-NNP-HIF1α
Ape-C-NNP
dtBBB-NNP-Oligo
Program
Indication(s)
Inflammatory 
and Autoimmune Diseases
Inflammatory 
Bowel Disease
Cold Tumor
Diabetic Ulcer
Pulmonary Arterial Hypertension
Alzheimer's Disease
Targeting moiety
SIRPα
SIRPα
SIRPα
Collagen binding domain
CAR peptide
Undisclosed
Therapeutic cargo
Mesencymal 
stem cell factors
NLRP3 ASO
Undisclosed
HIF1α transcription factor
Apelin peptide
Undisclosed